Zimmer Biomet (ZBH) Competitors

$83.42 +0.59 (+0.71%)

As of 03:36 PM Eastern

ZBH vs. PEN, MDLN, GEHC, PHG, and SNN

Should you be buying Zimmer Biomet stock or one of its competitors? The main competitors of Zimmer Biomet include Penumbra (PEN), Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

: 88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 4.2% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Zimmer Biomet currently has a consensus target price of $102.80, indicating a potential upside of 23.55%. Penumbra has a consensus target price of $362.93, indicating a potential upside of 11.68%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Penumbra.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
3 Sell rating(s)
12 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.26
Penumbra
0 Sell rating(s)

14 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.18
: Zimmer Biomet has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
: In the previous week, Penumbra had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 11 mentions for Penumbra and 5 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.80 beat Penumbra's score of 0.44 indicating that Zimmer Biomet is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Penumbra
6 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zimmer Biomet $8.23B 1.96 $705.20M $3.85 21.61
Penumbra $1.40B 9.11 $177.69M $4.52 71.90
: Penumbra has a net margin of 12.66% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Penumbra's return on equity.
Company Net Margins Return on Equity Return on Assets
Zimmer Biomet 9.05% 13.24% 7.28%
Penumbra 12.66% 11.41% 8.83%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.96	$705.20M	$3.85	21.61
Penumbra	$1.40B	9.11	$177.69M	$4.52	71.90

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Penumbra	12.66%	11.41%	8.83%

Summary

Zimmer Biomet beats Penumbra on 9 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Medline?

Medline (NASDAQ:MDLN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

: 88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.
Company Net Margins Return on Equity Return on Assets
Medline N/A N/A N/A
Zimmer Biomet 9.05% 13.24% 7.28%
: In the previous week, Medline had 13 more articles in the media than Zimmer Biomet. MarketBeat recorded 18 mentions for Medline and 5 mentions for Zimmer Biomet. Medline's average media sentiment score of 1.34 beat Zimmer Biomet's score of 0.80 indicating that Medline is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Zimmer Biomet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Medline presently has a consensus target price of $50.88, indicating a potential upside of 23.00%. Zimmer Biomet has a consensus target price of $102.80, indicating a potential upside of 23.55%. Given Zimmer Biomet's higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Medline.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
0 Sell rating(s)
6 Hold rating(s)

21 Buy rating(s)

2 Strong Buy rating(s)
2.86
Zimmer Biomet
3 Sell rating(s)

12 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.26
: Zimmer Biomet has lower revenue, but higher earnings than Medline.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Medline $28.43B 1.91 N/A N/A N/A
Zimmer Biomet $8.23B 1.96 $705.20M $3.85 21.61

Company	Net Margins	Return on Equity	Return on Assets
Medline	N/A	N/A	N/A
Zimmer Biomet	9.05%	13.24%	7.28%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medline	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medline	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.86
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medline	$28.43B	1.91	N/A	N/A	N/A
Zimmer Biomet	$8.23B	1.96	$705.20M	$3.85	21.61

Summary

Zimmer Biomet beats Medline on 7 of the 13 factors compared between the two stocks.

How does Zimmer Biomet compare to GE HealthCare Technologies?

Zimmer Biomet (NYSE:ZBH) and GE HealthCare Technologies (NASDAQ:GEHC) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

: Zimmer Biomet currently has a consensus target price of $102.80, indicating a potential upside of 23.55%. GE HealthCare Technologies has a consensus target price of $80.67, indicating a potential upside of 31.49%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, analysts clearly believe GE HealthCare Technologies is more favorable than Zimmer Biomet.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
3 Sell rating(s)
12 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.26
GE HealthCare Technologies
1 Sell rating(s)

8 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.41
: Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GE HealthCare Technologies has raised its dividend for 1 consecutive years.
: Zimmer Biomet has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, GE HealthCare Technologies has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
: GE HealthCare Technologies has a net margin of 9.10% compared to Zimmer Biomet's net margin of 9.05%. GE HealthCare Technologies' return on equity of 20.46% beat Zimmer Biomet's return on equity.
Company Net Margins Return on Equity Return on Assets
Zimmer Biomet 9.05% 13.24% 7.28%
GE HealthCare Technologies 9.10% 20.46% 5.73%
: 88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 82.1% of GE HealthCare Technologies shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 0.4% of GE HealthCare Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, GE HealthCare Technologies had 33 more articles in the media than Zimmer Biomet. MarketBeat recorded 38 mentions for GE HealthCare Technologies and 5 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.80 beat GE HealthCare Technologies' score of 0.69 indicating that Zimmer Biomet is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
GE HealthCare Technologies
16 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Positive
: GE HealthCare Technologies has higher revenue and earnings than Zimmer Biomet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zimmer Biomet $8.23B 1.96 $705.20M $3.85 21.61
GE HealthCare Technologies $20.98B 1.33 $2.08B $4.18 14.68

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
GE HealthCare Technologies	1 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.41

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
GE HealthCare Technologies	9.10%	20.46%	5.73%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GE HealthCare Technologies	16 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.96	$705.20M	$3.85	21.61
GE HealthCare Technologies	$20.98B	1.33	$2.08B	$4.18	14.68

Summary

GE HealthCare Technologies beats Zimmer Biomet on 12 of the 20 factors compared between the two stocks.

How does Zimmer Biomet compare to Koninklijke Philips?

Zimmer Biomet (NYSE:ZBH) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

: 88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: Zimmer Biomet currently has a consensus target price of $102.80, suggesting a potential upside of 23.55%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, equities research analysts clearly believe Zimmer Biomet is more favorable than Koninklijke Philips.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
3 Sell rating(s)
12 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.26
Koninklijke Philips
0 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. Koninklijke Philips pays an annual dividend of $0.86 per share and has a dividend yield of 3.2%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Koninklijke Philips pays out 81.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
: Zimmer Biomet has a net margin of 9.05% compared to Koninklijke Philips' net margin of 5.09%. Koninklijke Philips' return on equity of 13.68% beat Zimmer Biomet's return on equity.
Company Net Margins Return on Equity Return on Assets
Zimmer Biomet 9.05% 13.24% 7.28%
Koninklijke Philips 5.09% 13.68% 5.59%
: Zimmer Biomet has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, Koninklijke Philips has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
: In the previous week, Koninklijke Philips had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 11 mentions for Koninklijke Philips and 5 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 0.80 beat Koninklijke Philips' score of 0.80 indicating that Zimmer Biomet is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Koninklijke Philips
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Koninklijke Philips has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zimmer Biomet $8.23B 1.96 $705.20M $3.85 21.61
Koninklijke Philips $17.83B 1.47 $1.01B $1.06 25.75

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Koninklijke Philips	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Koninklijke Philips	5.09%	13.68%	5.59%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	2 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.96	$705.20M	$3.85	21.61
Koninklijke Philips	$17.83B	1.47	$1.01B	$1.06	25.75

Summary

Zimmer Biomet beats Koninklijke Philips on 12 of the 19 factors compared between the two stocks.

How does Zimmer Biomet compare to Smith & Nephew SNATS?

Zimmer Biomet (NYSE:ZBH) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

: 88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.2%. Smith & Nephew SNATS pays an annual dividend of $0.93 per share and has a dividend yield of 3.1%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend.
: Zimmer Biomet has higher revenue and earnings than Smith & Nephew SNATS.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zimmer Biomet $8.23B 1.96 $705.20M $3.85 21.61
Smith & Nephew SNATS $6.16B 2.09 $625M N/A N/A
: Zimmer Biomet has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
: Zimmer Biomet has a net margin of 9.05% compared to Smith & Nephew SNATS's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Smith & Nephew SNATS's return on equity.
Company Net Margins Return on Equity Return on Assets
Zimmer Biomet 9.05% 13.24% 7.28%
Smith & Nephew SNATS N/A N/A N/A
: In the previous week, Zimmer Biomet and Zimmer Biomet both had 5 articles in the media. Zimmer Biomet's average media sentiment score of 0.80 beat Smith & Nephew SNATS's score of 0.51 indicating that Zimmer Biomet is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Smith & Nephew SNATS
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Zimmer Biomet presently has a consensus target price of $102.80, suggesting a potential upside of 23.55%. Smith & Nephew SNATS has a consensus target price of $34.75, suggesting a potential upside of 15.12%. Given Zimmer Biomet's higher probable upside, equities research analysts clearly believe Zimmer Biomet is more favorable than Smith & Nephew SNATS.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
3 Sell rating(s)
12 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.26
Smith & Nephew SNATS
0 Sell rating(s)

4 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.23B	1.96	$705.20M	$3.85	21.61
Smith & Nephew SNATS	$6.16B	2.09	$625M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Smith & Nephew SNATS	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Smith & Nephew SNATS	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

Zimmer Biomet beats Smith & Nephew SNATS on 10 of the 15 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$16.10B	$8.19B	$6.22B	$22.93B
Dividend Yield	1.16%	2.47%	2.74%	4.03%
P/E Ratio	21.61	123.95	28.48	28.49
Price / Sales	1.96	8.10	535.62	14.42
Price / Cash	6.04	17.06	43.35	25.32
Price / Book	1.27	3.57	9.94	4.60
Net Income	$705.20M	$223.69M	$3.54B	$1.07B
7 Day Performance	1.06%	0.04%	1.34%	0.66%
1 Month Performance	-8.95%	12.94%	5.67%	6.86%
1 Year Performance	-11.78%	3.95%	42.64%	31.11%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	4.1452 of 5 stars	$83.42 +0.7%	$102.80 +23.2%	-10.2%	$16.11B	$8.23B	21.63	17,000
PEN Penumbra	2.6371 of 5 stars	$324.77 -0.2%	$364.60 +12.3%	+11.0%	$12.80B	$1.40B	71.85	4,700	News Coverage Earnings Report Analyst Forecast
MDLN Medline	N/A	$44.17 -1.3%	$50.62 +14.6%	N/A	$58.79B	$28.43B	N/A	43,000	Trending News Earnings Report Analyst Forecast
GEHC GE HealthCare Technologies	4.9199 of 5 stars	$61.00 0.0%	$82.00 +34.4%	-8.1%	$27.76B	$20.63B	14.59	54,000
PHG Koninklijke Philips	2.4173 of 5 stars	$26.27 +0.4%	N/A	+12.8%	$25.19B	$20.17B	24.78	65,340	Trending News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SNN

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Medline?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Summary

How does Zimmer Biomet compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SNN

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Medline?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Summary

How does Zimmer Biomet compare to Smith & Nephew SNATS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools